The clinical nutrition industry is shifting from supportive care to front-line therapy, as hospitals increasingly recognize its role in reducing complications, hospital stays, and mortality. With global market size rising from USD 52.6 billion in 2023 to USD 78.4 billion by 2030, at a CAGR of 5.9%, the focus has moved to precision nutrition in critical care, oncology, and aging populations. Nearly 60–65% of ICU patients now receive some form of tailored enteral or parenteral nutrition, contributing to improved outcomes and cost savings.
Driven by the dual burden of malnutrition and non-communicable diseases, Asia-Pacific is seeing record adoption rates growing at 7.2% CAGR, with government-funded programs expanding in India, Indonesia, and China. Meanwhile, North America continues to dominate with over 35% global market share, largely due to reimbursement coverage and high rates of chronic illness. Clinically fortified nutrition rich in whey protein, glutamine, arginine, and omega-3s has been proven to reduce post-surgical infection rates by 20–25%, and accelerate wound healing by up to 28%.
Download the full transcript for deep dives into reimbursement shifts, disease-linked demand, and how next-gen formulas are reshaping recovery science.
Cell therapies are moving from clinical trials into commercial-scale production, as both U.S. and EU regulators accelerate pathways for innovative treatments. By 2025, over 65% of advanced therapy medicinal products (ATMPs) in development are expected to enter early commercialization in specialized facilities, scaling to 85% by 2030. The market is projected to grow from USD 12.4 billion in 2025 to USD 28.1 billion by 2030, driven by oncology, autoimmune disorders, and rare disease indications.
Manufacturing scale-up remains a significant challenge, with batch-to-batch variability, cleanroom capacity, and automated bioreactor systems at the forefront. Early adopters in the U.S. and EU are reporting production yield increases of 20–30%, while cost per dose is expected to decline by 15–20% with modular and automated production platforms. Regulatory frameworks in the EU (EMA ATMP guidelines) and the U.S. (FDA Regenerative Medicine Advanced Therapy (RMAT) designation) are streamlining approval processes, but compliance costs are still high, averaging $4–6 million per facility per year. Strategic partnerships and contract manufacturing organizations (CMOs) are playing a key role in market entry and global distribution.
Cell therapy commercialization is no longer experimental scaling production, navigating global regulations, and leveraging innovative manufacturing platforms are essential for sustainable growth and competitive market entry in the U.S. and EU.
5 Key Quantitative Takeaways (2025–2030):
Download the full report to explore manufacturing scale-up strategies, regulatory pathways, and commercialization frameworks for cell therapy in U.S. and EU markets.
The role of healthcare facility management (HFM) is expanding from background operations to core strategy as hospitals race to modernize aging infrastructure and comply with stricter hygiene, sustainability, and safety mandates. The global HFM market is expected to grow from USD 429.8 billion in 2023 to USD 657.4 billion by 2030, at a CAGR of 6.3%. Hospitals are increasingly turning to integrated facility management (IFM) providers for bundled services, including waste disposal, HVAC, security, and energy optimization, freeing up resources to focus on patient care.
Across the board, smart facility tech is gaining traction: from predictive maintenance sensors and IoT-enabled utility tracking to digital twin models that help reduce system failures and downtime. In fact, leading hospitals using such tools have achieved 25% energy cost savings, 20–30% faster issue resolution, and reduced infection control risk by over 15%. While North America holds 38% of the market, the Asia-Pacific region is growing fastest, led by public-private infrastructure partnerships and digital health infrastructure expansion.
5 Key Quantitative Takeaways :
Download the expert transcript for benchmarking strategies, regional adoption maps, and emerging opportunities across infrastructure, compliance, and ESG-driven facility upgrades.
The global skin cancer diagnostics and therapeutics market is entering a pivotal growth phase, shaped by both alarming incidence rates and cutting-edge innovation in early detection and personalized care. In 2024 alone, over 1.3 million new skin cancer cases were reported globally, with non-melanoma skin cancer (NMSC) comprising nearly 75% of the total burden. This rising tide is driving the market from USD 9.8 billion in 2023 toward an expected USD 14.2 billion by 2030, growing at a CAGR of 5.3%. Against the backdrop of ozone depletion, aging populations, and tanning culture in developed economies, both diagnostics and therapeutics are gaining prominence in healthcare budgets.
Our expert-led transcript highlights how the diagnostics segment is rapidly evolving through AI-enhanced dermoscopy, liquid biopsy, and teledermatology, enabling detection accuracy of over 90% in clinical trials. On the therapeutic front, targeted therapies and immune checkpoint inhibitors are reshaping late-stage melanoma care, with new combinations improving 3-year survival rates by up to 45%. Meanwhile, regions like North America and Western Europe account for 60%+ of total market revenue, yet the Asia-Pacific region is expected to grow at 6.5% CAGR, owing to expanded skin health screening programs and urban sun exposure risks.
Here’s why the market’s momentum is impossible to ignore:
5. Strategic Insights & Market Signals:
Download the complete expert transcript to explore breakthrough innovations, regional access gaps, and strategic growth areas defining the future of skin cancer care.
The global compression therapy industry is undergoing a silent revolution—one that’s redefining how chronic vascular disorders, post-operative recovery, and diabetic complications are managed worldwide. With the market valued at USD 3.9 billion in 2023 and expected to reach USD 5.4 billion by 2030, this isn’t just incremental growth it’s a shift toward accessible, non-invasive, and cost-effective vascular solutions. Driven by the rising prevalence of venous ulcers, deep vein thrombosis (DVT), and lymphedema, demand is expanding across hospitals, rehabilitation centers, and homecare settings.
Our expert transcript dives deep into the evolving dynamics of this market. Today, static compression garments make up over 60% of total sales due to affordability and ease of use, while pneumatic and dynamic devices are accelerating in hospitals and sports recovery clinics. Regionally, North America commands the largest share (~40%) due to reimbursement policies and early diagnosis trends. However, Asia-Pacific is witnessing the fastest growth at over 6% CAGR, backed by expanding ambulatory care, rising public awareness, and the surge of chronic conditions among urban populations. Innovation is a major driver; smart compression sleeves, sensor-based monitoring, and remote adherence tracking are expected to boost patient compliance and long-term outcomes.
5. Key Strategic Insights & Market Signals:
Don’t miss out on the full breakdown of trends, forecasts, and expert insights. Download the full transcript now and discover how compression therapy is shaping the future of non-invasive care.